RxDoctor Payments Data

Graciela Calatayud, MD

Family Medicine · Huntington Park, CANPI 1336252352

Payments from drug & device makers

$13,520in general payments, 2019–2025

Across 63 payments — averaging $214.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Astrazeneca UK Limited$3K
  • Lilly USA, LLC$529
  • Amarin Pharma, Inc.$163
  • GSK$153
  • plus $564 from 10 others

What the payments were for

  • Food & beverage$1,619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,520 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$41,952
Medicare patients
91
Services billed
699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate106$117,284
OzempicSemaglutide33$36,031
FarxigaDapagliflozin Propanediol21$30,276
EliquisApixaban28$24,048
ProliaDenosumab13$21,456
Icosapent Ethyl96$20,388
JardianceEmpagliflozin12$16,728
Dexlansoprazole DrDexlansoprazole19$6,412
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,513
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$4,487
Qvar RedihalerBeclomethasone Dipropionate16$4,018
Albuterol Sulfate HfaAlbuterol Sulfate90$2,772
Alendronate Sodium263$2,699
Losartan Potassium237$2,392
Simvastatin291$2,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$56$117,284106 claims
Novo NordiskOzempic$119$36,03133 claims
AstraZenecaFarxiga$6,386$30,27621 claims
PfizerEliquis$24$24,04828 claims
AmgenProlia$98$21,45613 claims
Boehringer IngelheimJardiance$49$16,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Huntington Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →